Introduction {#S1}
============

Cholesterol metabolism in the brain is independent of peripheral tissues due to the blood-brain barrier (BBB) that impairs the entrance of the protein-bound lipid into the central nervous system (CNS). Brain tissues contain large amounts of cholesterol, up to 25% of the body's cholesterol content ([@B13]) whose metabolism and complex homeostasis regulation in the CNS remain unclear ([@B82]). Changes in this metabolism are related to neurodegenerative pathologies, such as Alzheimer's disease (AD), Parkinson's disease, and Huntington's disease, as well as to age-related cognitive decline ([@B59]; [@B42]).

Soluble epoxide hydrolase (sEH), a bifunctional enzyme possessing two different catalytic activities, is found in all regions of the brain ([@B69]). The C-terminal domain of its polypeptide chain exhibits EH activity, whereas the N-terminal domain presents phosphatase activity ([@B53]). The role of sEH's C-terminal domain has been extensively investigated (reviewed in [@B31]; [@B51]; [@B25]), but the role of its N-terminal domain is still poorly understood (see [Table 1](#T1){ref-type="table"}). Endogenous substrates for sEH N-terminal activity appear to be phosphorylated lipids, some of which are precursors in the cholesterol biosynthesis pathway and for protein isoprenylation ([@B15]), as well as lysophosphatidic acids and sphyngosine-1-phosphate ([@B57]; [@B53]). Considering the abundance of cholesterol in the CNS, it is important to further investigate the role of sEH in the brain cholesterol pathway.

###### 

Summary of studies investigating the roles of the carboxy- and the amino terminal domains of the soluble epoxide hydrolase enzyme.

  Soluble epoxide hydrolase                      Effects                                                                                                                                                                                                                                                    Experimental models                                                        References
  ---------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------- ----------------
  **C-terminal domain (hydrolase activity)**     Expression of human sEH domain alone reduces cholesterol levels.                                                                                                                                                                                           Cell culture of HepG2 cell line and sEH-knockout mice                      [@B16]
                                                 C-terminal inhibitor promotes neuroprotective effects, such as attenuation of oxidative stress, apoptosis, protein aggregation, and endoplasmic reticulum stress.                                                                                          C57BL/6J mice MPTP-induced neurotoxicity                                   [@B30]
                                                 sEH inhibition protects neurons and suppresses cytokine production and microglial migration into the hippocampus.                                                                                                                                          Male C57BL/6 mice global cerebral ischemia-induced                         [@B70]
                                                 C-terminal inhibition promotes antidepressant effect, increase of hippocampal BDNF expression, and neurogenesis.                                                                                                                                           Male C57BL/6 mice                                                          [@B76]
                                                 Inhibition of C-domain increases the memory response, reduces oxidative stress, minimizes inflammation, and decreases the level of the amyloid precursor protein in the brain.                                                                             Male Sprague-Dawley rats streptozotocin-induced Alzheimer's disease-like   [@B58]
                                                 Inhibition of C-terminal domain enhanced neuronal synaptic neurotransmission in the PFC associated with enhanced postsynaptic glutamatergic receptor and long-term potentiation (LTP) *via* extracellular signal-regulated kinase (ERK) phosphorylation.   Brain slices of C57BL/6 mice                                               [@B75]
  **N-terminal domain (phosphatase activity)**   Negatively regulates eNOS activity and NO production                                                                                                                                                                                                       Cell culture of bovine aortic endothelial cells and sEH-knockout mice      [@B28], [@B29]
                                                 Expression of human sEH phosphatase domain alone increases cholesterol levels.                                                                                                                                                                             Cell culture of HepG2 cell line and sEH-knockout mice                      [@B16]
                                                 Arg287Gln variant is linked to increased levels of plasma cholesterol and of triglycerides in patients with familial hypercholesterolemia.                                                                                                                 Human blood plasma                                                         [@B64]

This review aims to summarize the role of sEH in mammals and its protein structure and catalytic activities. We also provide a compilation of sEH distribution and expression in the human brain and deepen the discussion on the enzyme's N-terminal phosphatase activity and its involvement in the synthesis of cholesterol. Finally, we discuss cholesterol metabolism and its implication in AD.

Soluble Epoxide Hydrolase {#S2}
=========================

Vertebrate sEHs are members of the EH family ubiquitously found in nature ([@B14]; [@B56]; [@B51]). EHs open epoxides to form diols by the addition of a water molecule ([@B19]). In mammals, this enzyme is broadly distributed in different tissues. The subcellular localization of sEH follows a tissue-specific pattern, by which the protein can be exclusively located in the cytosol or additionally present in peroxisomes ([@B14]; [@B56]; [@B15]; [@B37]). Mammals have several EH isoforms, the most known of which are the microsomal EH (mEH) and sEH ([@B12]). Two other EHs have been described, EH3 and EH4, and they represent a new family of mammalian EHs. EH3 is mostly expressed in the lung, skin, and upper gastrointestinal tract and features a high activity for fatty acid-derived epoxides ([@B11]).

In humans, the bifunctional enzyme is located intracellularly, both in the cytosol and in peroxisomes ([@B56]), with a broad distribution in all tissues ([@B14]; [@B69]). A function for sEH was first described in the metabolism of xenobiotic compounds by the kidney and the liver ([@B12]). While the detoxifying role of hepatic and renal sEH has been carefully addressed ([@B32]; [@B31]), much less is known about the role of the sEH in the brain.

Distribution and Expression of sEH in the Brain {#S3}
===============================================

In the human CNS, the sEH is distributed in all regions of the brain, mostly in neuronal cell bodies, as well as in astrocytes and oligodendrocytes. It also occurs in a relatively high abundance in the ependymal cells of the choroid plexus and in the smooth muscle of brain arterioles ([@B69]). In the brain of mice, immunoreactivity for sEH was found only in neurons of the central amygdala, which also contained mEH. Rather than in neurons, in other CNS regions, sEH was located in astrocytes ([@B48]; [@B24]). Neurons in the nucleus, which represent an important output of the amygdala, express a number of neuropeptides, the release of which are thought to recruit BK~*Ca*~ channels for calcium signaling, in most neuronal secretory cells ([@B6]). Epoxyeicosatrienoic acids (EETs) and/or dihydroxyeicosatrienoic acids (DHETs) could play a role on neuropeptide release because of their well-known actions on BK~*Ca*~ channels. Accordingly, it has been shown that 14,15-EET has a role in the release of oxytocin and vasopressin ([@B55]), somatostatin ([@B36]), and β-endorphin and Met-enkephalin ([@B71]). Altogether, it is possible that the exclusive neuronal presence of sEH in the central amygdala might have a function in the release of neuropeptides.

Blockage of sEH activity, either through pharmacological inhibition or genetic deletion, revealed its neuroprotective effects. In sEH knockout mice, decreased infarct volumes, elevated brain-derived neurotrophic factor (BDNF) expression, and increased production of astrocyte-derived BDNF were reported, all favoring astrocyte viability and protecting neurons from ischemic injury ([@B81]). sEH activity affects basal synaptic transmission and synaptic plasticity. Furthermore, its inhibition improves neuronal synaptic neurotransmission mediated by an increase of postsynaptic glutamatergic receptors and long-term potentiation, which is boosted *via* extracellular signal-regulated kinase (ERK) phosphorylation ([@B75]), suggesting that inhibition of sEH could modulate learning and memory formation. sEH inhibitors have thus been proposed as potential therapeutic agents for the prevention and treatment of injuries to the CNS.

sEH Protein Structure {#S3.SS1}
---------------------

The human sEH is a 62.5-kDa enzyme, product of the EPXH2 gene, located on chromosome 8. This gene (45 kb) contains 19 exons encoding a protein of 555 amino acid residues ([@B51]) and encodes a two-domain, bifunctional enzyme as result of a gene fusion event ([@B3]). In mammals, sEH is a homodimer composed of two globular monomers, where each monomer comprises two distinct structural domains, the N- and C-terminal regions, separated by a short proline-rich linker ([@B56]). The dimer shows an "antiparallel" organization of the monomers, in such a way that the C-terminal region of one monomer faces the N-terminal region of the other. The structural features of sEH are depicted in [Figure 1](#F1){ref-type="fig"}. The C-terminal domain (EC 3.3.2.10), ∼35 kDa, exhibits EH activity, which opens an epoxide ring to form the corresponding diol. On the other hand, the N-terminal domain (EC 3.1.3.76), ∼25 kDa, has phosphatase activity toward lipid phosphates, such as isoprenoid phosphates, lysophosphatidic acids, and sphingosine-1-phosphate ([@B24]; [@B51]; [@B52]). The domain-swapped architecture of sEH aids in the enzyme's stability and enables exchange of two distinct unrelated substrates ([@B1]). The combined phosphatase and EH domains in this bifunctional enzyme reflects a positive selective advantage of a gene fusion event between ancient members of two distinct superfamilies of dehalogenases. Single-domain EHs are found in plants, invertebrates, and fungi and show homology to prokaryotic haloalkane dehalogenase ([@B3]; [@B23]). The activity of the N-terminal domain of the first "fused" enzymes was only vestigial ([@B3]) and evolved through mutations to the present phosphatase domain of vertebrate sEH, whose enzyme activity was discovered only in 2003 ([@B8]; [@B56]). Orthologs of the vertebrate sEH phosphatase domain were described in the genome of *Caenorhabditis elegans* as well as in Archea and Bacteria ([@B23]; [@B24]).

![Soluble epoxide hydrolase (sEH): structure and known physiological roles. **(A)** Structure of sEH's monomer, with the N- and C-terminal domains separated by a proline-rich linker. The SNP R287Q, located in the C-terminal domain, results in a lower hydrolase activity. **(B)** Overall structure of the dimeric form of the human sEH, showing the two monomers and their respective domains N- and C-termini, which are globular regions with alpha and beta structures connected by a proline-rich linker. The amino terminal domain displays a phosphatase activity, whereas the carboxy terminal domain carries a hydrolase activity. **(C)** The sEH's phosphatase activity is involved in brain cholesterol metabolism. Higher brain cholesterol content may increase the levels of amyloid precursor protein (APP), thus contributing to the pathogenesis of Alzheimer's disease (AD). **(D)** The sEH activity performs the hydration of epoxide groups of all six regioisomers of neuroprotective epoxyeicosatrienoic acids (EET), forming the corresponding inactive dihydrodiols.](fnmol-12-00325-g001){#F1}

Catalytic Activities of sEH {#S4}
===========================

Epoxide Hydrolase {#S4.SS1}
-----------------

The sEH C-terminal EH domain metabolizes all four regioisomers of EET, which are lipid autacoids derived from arachidonic acid by the action of cytochrome P450 epoxygenases. sEH introduces a water molecule into epoxide ring to form the corresponding DHET ([Figure 1](#F1){ref-type="fig"}), thereby diminishing or eliminating the biological effects of EET ([@B80]).

Studies with potent selective inhibitors, such as 1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) urea, N-\[1-(1-Oxopropyl)-4-piperidinyl\]-N′-\[4-(trifluoromethoxy)ph enyl\] urea (TPPU), or 12-\[\[(tricyclo \[3.3.1.13,7\] dec-1-ylamino) carbonyl\] amino\]-dodecanoic acid (AUDA), have indicated that inhibition of sEH activity promotes anti-inflammatory, antihypertensive, neuroprotective, and cardioprotective effects ([@B68]). These beneficial effects correlated to an increase of the circulating levels of EET, which contribute to halt the progression of hypertension, cardiovascular pathologies, hypercholesterolemia, and of inflammatory diseases ([@B72]).

Phosphatase Activity {#S4.SS2}
--------------------

The physiological role and the endogenous substrate(s) of the sEH phosphatase activity are still elusive. Studies performed *in vitro* indicated that sEH phosphatase activity hydrolyzes lipid phosphates, like isoprenoid phosphates, which are precursors of cholesterol biosynthesis and protein isoprenylation ([@B15]). Morisseau and collaborators ([@B53]) have demonstrated that lysophosphatidic acids (LPAs) are excellent substrates for sEH phosphatase activity. LPAs bind to various nuclear receptors and regulate cell survival, apoptosis, motility, shape, differentiation, gene transcription, and malignant transformation ([@B67]; [@B41]). Moreover, LPA inhibits pre-adipocyte differentiation, thus limiting adipogenesis through interaction with PPARγ ([@B54]). This nuclear receptor plays an essential role in regulating lipid and glucose homeostasis.

Several groups have shown that fatty acid epoxide substrates and diol products of sEH activate peroxisome proliferator-activated receptors (PPARs) ([@B57]; [@B33]). The exact role of sEH in modulating PPARs is currently unknown, albeit the significance of PPARs in lipid metabolism and metabolic disorders is well-documented ([@B39]; [@B7]).

Soluble epoxide hydrolase also plays a pivotal role in the regulation of endothelial nitric oxide (NO) synthase (eNOS) activity and NO-mediated endothelial cell functions ([@B28]). Endothelium-derived NO is a crucial regulator of vascular homeostasis ([@B65]). NO bioavailability is tightly controlled by NOS activity. The phosphatase activity of sEH downregulates activated eNOS signaling and NO production. Inhibition of sEH phosphatase activity was shown to increase NO production and prolong the phosphorylation of eNOS ([@B28]; [@B29]). In the nervous system, NO has both physiological and pathological functions. For example, NO contributes to long-term potentiation (LTP), playing a role in learning and memory processes ([@B66]). NO enhances the expression of cAMP response element binding protein (CREB) to mediate the response to BDNF ([@B63]). NO also mediates glutamate-NMDA receptor (NMDAr) signaling in neurons ([@B34]; [@B77]).

To date, different molecules with inhibitory effect toward the phosphatase activity of sEH have been described, even though most lack a potent and selective chemical action. Kramer and collaborators reported ([@B38]) in 2019 the synthesis of the first *in vivo* inhibitor of both the human and rat sEH phosphatase domains, 4-(4-(3,4-dichlorophenyl)-5-phenyloxazol-2-yl) butanoic acid (SWE101), with an IC~50~ 0.058 μM against the human enzyme. SWE101 showed adequate pharmacokinetic properties in rats, allowing studies on the pathophysiological relevance of phosphatase activity of sEH and revealing its role on the hydrolysis of lysophosphatidic acids ([@B37]; [@B38]).

sEH Phosphatase Activity and Synthesis of Cholesterol {#S5}
=====================================================

Epidemiological studies have associated sEH polymorphisms with various human diseases, many of which are related to cardiovascular disorders and familial hypercholesterolemia ([@B64]). The R287Q variant was described as an emerging risk factor for atherosclerosis. This polymorphism correlated positively with subclinical atherosclerosis and coronary artery calcification ([@B18]; [@B74]). The R287Q variant is also linked to increased levels of plasma cholesterol and triglycerides in patients with familial hypercholesterolemia ([@B64]). This sEH variant displays a higher isoprenoid phosphatase activity *in vitro* ([@B15]). Another variant, sEH K55R, leads to an increased sEH activity *in vivo* and was correlated with coronary heart disease ([@B40]). The single-nucleotide polymorphisms (SNPs) cited above occur in two different exons of the EPHX2 gene. The former, located in the eighth exon, results in a change of the amino acid (arginine to glutamine) in position 287 in the C-terminal domain and a lower hydrolase activity. The latter SNP resides in the second exon, encoding an amino acid substitution (lysine to arginine) in the N-terminal domain of the polypeptide chain and causes an increase of the hydrolase activity ([@B62]).

Soluble epoxide hydrolase-knockout mice have lower cholesterol levels as well as several of its precursors, besides reduced plasma steroid concentration. This was accompanied by a general decrease in serum lipids ([@B16]; [@B44]). Studies with recombinant HepG2 cells expressing either the phosphatase domain or the hydrolase domain alone have demonstrated the independent and opposite roles of the two sEH enzymatic activities. The C-terminal activity lowered the cell's cholesterol level while the N-terminal activity was found to increase it ([@B16]). Treatment of wild-type mice with a hydrolase inhibitor resulted in higher cholesterol levels, thus mimicking the effect of expressing the phosphatase domain alone in HepG2 cells ([@B16]).

Besides its direct catalytic activity on so far unidentified substrate(s), sEH further affects cholesterol metabolism by modulating the expression of the rate-limiting enzyme in cholesterol synthesis, HMG CoA reductase, *via* the activation of AMPK and inhibition of SREBP1/2 ([@B47]). Moreover, sEH deletion also affected the basal and insulin-induced expressions of low-density lipoprotein (LDL) receptor and of fatty acid synthase ([@B47]).

Altogether, these results suggest a potential role of sEH in regulating cholesterol biosynthesis and metabolism.

Brain Cholesterol Metabolism {#S6}
============================

Cholesterol is an essential molecule for the neuronal physiology during early development as well as in the adult life, and its levels must be precisely maintained to allow for its correct function. Both neurons and glial cells produce enough cholesterol for their survival. Cholesterol is necessary for the growth of axons and dendrites during organogenesis, nerve regeneration, remodeling, and neuronal repair ([@B5]; [@B10]; [@B46]). Additional amounts are required for the formation of mature synapses, and synaptogenesis might be limited by the availability of cholesterol ([@B50]).

Cholesterol synthesis and metabolism in the brain fully rely on *de novo* synthesis. The BBB, which prevents cholesterol uptake from the circulation, and the blood-cerebrospinal fluid (CSF) barrier (plasma is ultrafiltrated to be part of the CSF) are two natural barriers that prevent mixing of plasma and brain cholesterol ([@B20]; [@B21]).

Similar to peripheral cholesterol synthesis, brain cholesterol is synthesized from acetyl-CoA in a complex biosynthetic pathway catalyzed by at least 20 enzymes, including the rate-limiting HMG-CoA reductase ([@B20]). In glial cells, brain cholesterol is converted mainly into 24-hydroxycholesterol (24-OHC) or oxidized into 27-hydroxycholesterol (27-OHC). The latter regulates cholesterol transport in neurons by acting on a nuclear transcription factor that controls the expression of ApoE and ABCA1/ABCG1 ([@B9]). Such oxysterols are important to maintain brain cholesterol homeostasis.

The expression levels of cholesterol 24-hydroxylase, a cytochrome P450 enzyme (CYP46A1), is about 100-fold higher in the brain than in the liver. This enzyme catalyzes the conversion of CNS cholesterol to 24-OHC, an oxidized catabolite denominated oxysterol. Most of the oxysterol flows out from the brain into the blood through the BBB, powered by the concentration gradient, while a small amount flows into the CSF ([@B45]; [@B4]). In contrast, the catabolic pathway of cholesterol *via* oxidation in the liver has as final products the bile acids ([@B43]).

To evaluate the importance of the 24-hydroxylation pathway in cholesterol turnover, Lund and collaborators ([@B43]) conducted studies in cholesterol 24-hydroxylase knockout mice (CYP46A1\_/\_), showing that *de novo* cholesterol synthesis in the liver remained stable, whereas that in the brain was decreased by 40%. These data indicated that *de novo* cholesterol synthesis and the levels of 24-OHC are strongly linked, and that at least 40% of cholesterol turnover in the brain depends on cholesterol 24-hydroxylase. Thus, this enzyme constitutes an important tissue-specific pathway for cholesterol renewal in the brain.

24-hydroxycholesterol plasma levels, unlike other oxysterols, show an age-dependent correlation: in the first decade of life, the ratio between 24-OHC and cholesterol is about five times higher than it is in the sixth decade. Moreover, there is also a correlation between 24-OHC levels in the plasma and the CSF, indicating that 24-OHC efflux from the brain into the circulation is significant and necessary for cerebral cholesterol homeostasis ([@B45]).

A direct correlation between a decrease in plasma cholesterol concentration and in HMG-CoA reductase was shown by [@B16] in sEH-knockout male mice. Moreover, HepG2 cell lines subjected to inhibition of the sEH domain showed higher cholesterol levels. Altogether, these data suggest an involvement of sEH phosphatase domain in cholesterol metabolism. Thus, it is plausible to suggest that in the brain, a similar mechanism occurs, with the N-terminal domain of sEH regulating cholesterol metabolism, implying that higher levels of its phosphatase activity could potentially increase brain cholesterol concentrations.

Alzheimer's Disease and Cholesterol Metabolism {#S7}
==============================================

Alzheimer's disease is the most common neurodegenerative disorder worldwide and also the major cause of dementia in the elderly. Despite extensive research, no cure for this pathology has been found. Classical hallmarks for AD include extracellular senile plaques formed by the deposition of β-amyloid peptide (Aβ), excessive phosphorylation of the tau protein, and formation of intracellular neurofibrillary tangles---all these processes leading to loss of synapses, neuronal death, and proliferation of astrocytes ([@B49]).

Hypercholesterolemia is an important risk factor for AD and other neurodegenerative diseases. Plasma cholesterol levels are at least 10% higher in AD patients ([@B61]), and those patients with higher levels of total cholesterol seem to have a faster decline in cognitive abilities than the ones with normal cholesterol levels ([@B26]).

Disruptions in cholesterol metabolism are significantly associated with AD pathogenesis, even though it is uncertain if these are a cause or a consequence of the disease ([@B60]). The efflux of oxysterols from the brain into the blood plays a key role in this process ([@B42]). Genetic polymorphisms in proteins involved in energy metabolism or lipid transport are known as important risk factors for the development of this pathology, such as the presence of the allele ApoE4 of apolipoprotein E (ApoE), the most abundant apoprotein involved in cholesterol transport in the CNS ([@B27]). The presence of the ApoE4 allele is considered an important genetic risk factor for both early- and late-onset AD, accounting for 45--60% of AD patients ([@B17]).

Increased cholesterol levels in the brain appear to contribute to changes in cell membrane properties consequent to the increased contents of intracellular and membrane-bound cholesterol ([@B79]). The amyloid precursor protein (APP) is an integral transmembrane protein. When the amount of cholesterol in the cell membranes rises, it promotes the binding of APP to lipid rafts and its cleavage to form the β-amyloid peptides ([Figure 1](#F1){ref-type="fig"}; [@B2]). There are multiple β-amyloid forms, such as Aβs monomers, oligomers, and amyloid fibers. Aβs oligomers are the most toxic and recognized as the primary cause of cognitive decline in AD patients ([@B73]). Furthermore, high intracellular cholesterol levels increase the enzymatic activity of secretases involved in the amyloid metabolic pathway, resulting in a higher generation of Aβ ([@B22]).

The BBB plays an important role in limiting the entry of plasma components that are potentially neurotoxic, as well as pathogens and blood cells into the brain. Jiang and collaborators ([@B35]) found that a high-cholesterol diet (2% cholesterol supplementation for 10 weeks) fed to rabbits increased the BBB permeability when compared to animals receiving a normal diet. This increased BBB permeability enables the peripheral cholesterol to cross this barrier, leading to further increase of the CNS cholesterol levels ([@B79]). Thus, any dysfunction of the BBB can alter significantly the CNS environment, affecting its functions and structure, and plays a key role in the development and progression of AD.

[@B52] discovered a compound, called ebselen, which inhibits sEH phosphatase activity in a high-throughput screening enzyme-based assay. Ebselen binds to the N-terminal domain of sEH and chemically reacts with the enzyme to quickly and irreversibly block its phosphatase activity ([@B52]). Noteworthy, [@B78] reported in 2017 the potential of ebselen, a strong antioxidant, lipid-soluble, selenium-containing compound, in the treatment of cognitive dysfunction and neuropathology in a triple transgenic AD model in mice. Ebselen decreased the expression of amyloid precursor protein and β-secretase, reduced the levels of Aβ in AD neurons, especially the most toxic oligomeric form, and decreased phosphorylation of tau protein while increasing glutathione peroxidase and superoxide dismutase activities ([@B78]). The beneficial effects of ebselen were attributed solely to its antioxidant properties. However, these protective effects could also be, at least in part, related to the inhibition of sEH phosphatase activity and its consequent impact of lowering brain cholesterol levels.

Conclusion {#S8}
==========

Throughout the years, human sEH has been poorly studied in the context of CNS physiology, mainly the role of its phosphatase domain and its possible influence on brain cholesterol metabolism. Considering that the disruption in brain cholesterol is a key player in the onset of AD, as well as of other neurodegenerative diseases, it is crucial to deepen our understanding of the role of this enzyme in the CNS pathophysiology. In that view, sEH phosphatase domain may represent an underexploited target for drug design and development of therapeutic strategies to ameliorate the symptoms or delay the progress of neurodegenerative diseases.
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